KR100869752B1 - 레보시멘단의 약학적 액제 - Google Patents
레보시멘단의 약학적 액제 Download PDFInfo
- Publication number
- KR100869752B1 KR100869752B1 KR20027002923A KR20027002923A KR100869752B1 KR 100869752 B1 KR100869752 B1 KR 100869752B1 KR 20027002923 A KR20027002923 A KR 20027002923A KR 20027002923 A KR20027002923 A KR 20027002923A KR 100869752 B1 KR100869752 B1 KR 100869752B1
- Authority
- KR
- South Korea
- Prior art keywords
- solution
- pharmaceutically acceptable
- acid
- liquid formulation
- weight
- Prior art date
Links
- QKSZUHCKZRHCLW-UHFFFAOYSA-N CC(C1)C(c(cc2)ccc2NN=C(C)C)=NNC1=O Chemical compound CC(C1)C(c(cc2)ccc2NN=C(C)C)=NNC1=O QKSZUHCKZRHCLW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Cardiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
사이트릭 아시드mg/ml | 저장시간/침전생성물의 양 (OR-1746) | |
2-8℃ | 40℃ | |
0 | 5주/0.34% | 5주/10.9% |
0.25 | 13주/0.29% | 13주/6.2% |
0.50 | 13주/0.20% | 13주/4.4% |
0.75 | 13주/0.16% | 13주/3.5% |
1.00 | 13주/0.13% | 13주/3.0% |
1.50 | 13주/0.10% | 13주/2.2% |
2.00 | 13주/0.10% | 13주/1.7% |
사이트릭 아시드mg/ml | 저장시간/침전생성물의 양 (OR-1746) | |
2-8℃ | 40℃ | |
0 | 12개월/3.94% | nd |
2.0 | 4개월/0.20% 12개월/0.39% 18개월/0.59% | 4개월/5.6% nd nd |
2.5 | 4개월/0/16% 12개월/0.28% 18개월/0.47% | 4개월/3.2% nd nd |
0시간 | 24시간 | 1개월 | |
침전생성물OR-1420 | < | < | 0.1% |
침전생성물OR-1420 | 0.1% | 0.1% | < |
미지의 침전생성물 | < | < | < |
pH | 3.9 | nd | 3.9 |
레보시멘단 mg/ml | 0시간 | 2일 8-15℃/25℃ | 5일 8-15℃/25℃ | |
침전생성물OR-1420 | 0.01 0.1 0.25 | < 1.5% 0.4% | 1.6%/3.3% 1.1%/1.8% 0.8%/2.2% | 2.2%/6.0% 1.8%/5.3% 1.4%/4.2% |
미지의 침전생성물 | 0.01 0.1 0.25 | nd < < | nd 0.2%/0.4% 0.3%/0.5% | nd 0.2%/0.6% 0.3%/0.9% |
pH | 0.01 0.1 0.25 | 7.2 7.8 7.8 | 7.2/7.3 7.8/7.8 7.8/7.8 | 7.3/7.3 8.0/8.0 8.0/8.0 |
Claims (17)
- 활성성분으로서 레보시멘단 또는 그 염을 포함하며 용액의 pH값이 3~5인 약학적 수용성 액제.
- 삭제
- 삭제
- 제 1항에 있어서, 용액이 용해보조제를 함유하는 수용성 액제.
- 제 4항에 있어서, 용해보조제가 폴리비닐피롤리돈 또는 에탄올인 액제.
- 다음을 포함하는 약학적 액제(a) 활성성분으로서 레보시멘단 또는 그 염,(b) 약학적으로 허용되는 유기용제로 에탄올을 포함하고,(c) pKa 2 ~ 4의 범위를 가지는 약학적으로 허용되는 유기산의 안정성 증진량.
- 제 6항에 있어서, 유기용제의 양이 용액중량의 90~99.9중량% 액제.
- 제 6항에 있어서, 수용성 용해보조제를 더 함유하는 액제.
- 제 6항에 있어서, 용액이 수용성 정맥주사용 인퓨젼 용액인 액제.
- 삭제
- 제 6항에 있어서, 약학적으로 허용되는 유기산이 탄소수 3-6의 2-하이드록시 알카노익산인 액제.
- 제 6항 또는 11항에 있어서, 약학적으로 허용되는 유기산이 사이트릭 아시드, 락틱 아시드, 타타릭 아시드 또는 말릭 아시드인 인퓨젼 농축액.
- 제 6항 또는 제 11항에 있어서, 유기산의 양이 액제의 0.05~2중량%인 액제.
- 제 8항에 있어서, 용해보조제의 양이 0.1~5중량%인 액제.
- 제 8항 있어서, 용해보조제가 폴리비닐피롤리돈인 액제.
- 제 6항에 있어서, 액제가 정맥주사용 인퓨젼 농축액인 액제.
- 제 13항에 있어서, 용해보조제가 폴리비닐피롤리돈인 액제.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FI19991925 | 1999-09-10 | ||
FI991925A FI109659B (fi) | 1999-09-10 | 1999-09-10 | Levosimendaanin farmaseuttisia liuoksia |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20020048400A KR20020048400A (ko) | 2002-06-22 |
KR100869752B1 true KR100869752B1 (ko) | 2008-11-21 |
Family
ID=8555263
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR20027002923A KR100869752B1 (ko) | 1999-09-10 | 2000-09-08 | 레보시멘단의 약학적 액제 |
Country Status (39)
Country | Link |
---|---|
US (2) | US6730673B1 (ko) |
EP (1) | EP1210085B1 (ko) |
JP (1) | JP4708648B2 (ko) |
KR (1) | KR100869752B1 (ko) |
CN (1) | CN1203855C (ko) |
AR (1) | AR025449A1 (ko) |
AT (1) | ATE315937T1 (ko) |
AU (1) | AU771027B2 (ko) |
BG (1) | BG65827B1 (ko) |
BR (1) | BRPI0013924B8 (ko) |
CA (1) | CA2382013C (ko) |
CO (1) | CO5180582A1 (ko) |
CZ (1) | CZ303095B6 (ko) |
DE (1) | DE60025627T2 (ko) |
DK (1) | DK1210085T3 (ko) |
EA (1) | EA005067B1 (ko) |
EE (1) | EE05375B1 (ko) |
ES (1) | ES2256034T3 (ko) |
FI (1) | FI109659B (ko) |
HK (1) | HK1049282B (ko) |
HR (1) | HRP20020298B1 (ko) |
HU (1) | HU228340B1 (ko) |
IL (2) | IL148379A0 (ko) |
IS (1) | IS2244B (ko) |
ME (1) | ME00523B (ko) |
MX (1) | MXPA02002423A (ko) |
MY (1) | MY125984A (ko) |
NO (1) | NO331989B1 (ko) |
NZ (1) | NZ517605A (ko) |
PL (1) | PL202356B1 (ko) |
PT (1) | PT1210085E (ko) |
RS (1) | RS50445B (ko) |
SI (1) | SI1210085T1 (ko) |
SK (1) | SK287154B6 (ko) |
TR (1) | TR200200620T2 (ko) |
TW (1) | TWI242434B (ko) |
UA (1) | UA73954C2 (ko) |
WO (1) | WO2001019334A2 (ko) |
ZA (1) | ZA200201828B (ko) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI109659B (fi) * | 1999-09-10 | 2002-09-30 | Orion Yhtymae Oyj | Levosimendaanin farmaseuttisia liuoksia |
FI20010233A0 (fi) * | 2001-02-08 | 2001-02-08 | Orion Corp | Menetelmä sydämen vajaatoiminnan hoitoon |
CN100428937C (zh) * | 2003-10-30 | 2008-10-29 | 北京海合天科技开发有限公司 | 左西孟旦冷冻干燥组合物 |
CN100367964C (zh) * | 2004-04-29 | 2008-02-13 | 王思清 | 左西孟旦-β环糊精包含物制剂 |
JP2008530186A (ja) * | 2005-02-18 | 2008-08-07 | オリオン コーポレーション | 心不全治療法 |
JP2010514778A (ja) * | 2006-12-28 | 2010-05-06 | オリオン コーポレーション | 非経口投与のためのレボシメンダン製剤 |
WO2012093404A2 (en) | 2011-01-03 | 2012-07-12 | Gufic Biosciences Limited | Parenteral formulations of levosimendan |
US9597425B2 (en) * | 2011-10-18 | 2017-03-21 | St. Teresa Medical, Inc. | Method of forming a hemostatic product |
US9808529B2 (en) * | 2012-05-18 | 2017-11-07 | Luoda Pharma Pty Ltd | Liquid formulation |
CN105106113B (zh) * | 2015-09-30 | 2019-07-26 | 济南康和医药科技有限公司 | 一种左西孟旦注射液及其制备方法 |
EA034565B1 (ru) * | 2015-11-06 | 2020-02-20 | Каринофарм Гмбх | Композиции левосимендана для внутривенного введения в виде инфузии или инъекции и концентрата для инфузии |
WO2017083050A1 (en) | 2015-11-12 | 2017-05-18 | St. Teresa Medical, Inc. | A method of sealing a durotomy |
CN108261398A (zh) * | 2016-12-30 | 2018-07-10 | 齐鲁制药有限公司 | 一种含有左西孟旦的供注射用药物制剂及其制备方法 |
US10953128B2 (en) | 2017-11-02 | 2021-03-23 | St. Teresa Medical, Inc. | Fibrin sealant products |
CN111474289A (zh) * | 2019-10-31 | 2020-07-31 | 武汉嘉诺康医药技术有限公司 | 一种利用反相色谱分离分析左西孟旦中右西孟旦的方法 |
WO2021126884A1 (en) | 2019-12-16 | 2021-06-24 | Tenax Therapeutics, Inc. | LEVOSIMENDAN FOR TREATING PULMONARY HYPERTENSION WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (PH-HF-pEF) |
CN111514147B (zh) * | 2020-05-12 | 2021-09-17 | 成都欣捷高新技术开发股份有限公司 | 用于急性失代偿心力衰竭症状的左西孟旦钠药用组合物及制备方法 |
US11760730B2 (en) * | 2021-01-11 | 2023-09-19 | Navinta, Llc | Process for the preparation of high purity Levosimendan |
WO2023027670A2 (en) * | 2021-08-23 | 2023-03-02 | Tum Ekip Ilac Anonim Sirketi | Lyophilized levosimendan compositions |
CN115518037A (zh) * | 2022-10-14 | 2022-12-27 | 上药东英(江苏)药业有限公司 | 一种安全质量稳定的左西孟旦注射剂组合物及其制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998001111A1 (en) * | 1996-07-05 | 1998-01-15 | Orion-Yhtymä Oy | Transdermal compositions containing levosimendan |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2251615B (en) | 1991-01-03 | 1995-02-08 | Orion Yhtymae Oy | (-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]pro panedinitrile |
GB2266841A (en) | 1992-05-06 | 1993-11-17 | Orion Yhtymae Oy | Compounds for use as anti-ischemic medicaments |
GB9606474D0 (en) | 1996-03-27 | 1996-06-05 | Orion Yhytmo Oy | Method for obtaining pure enantiomers of a pyridazinone derivative |
FI980902A (fi) * | 1998-04-23 | 1999-10-24 | Orion Yhtymae Oyj | Levosimendaanin stabiileja koostumuksia |
FI109659B (fi) * | 1999-09-10 | 2002-09-30 | Orion Yhtymae Oyj | Levosimendaanin farmaseuttisia liuoksia |
-
1999
- 1999-09-10 FI FI991925A patent/FI109659B/fi active
-
2000
- 2000-08-09 UA UA2002042873A patent/UA73954C2/uk unknown
- 2000-08-11 MY MYPI20003682A patent/MY125984A/en unknown
- 2000-08-30 TW TW089117581A patent/TWI242434B/zh not_active IP Right Cessation
- 2000-08-30 AR ARP000104525A patent/AR025449A1/es not_active Application Discontinuation
- 2000-09-06 CO CO00067212A patent/CO5180582A1/es active IP Right Grant
- 2000-09-08 NZ NZ517605A patent/NZ517605A/en not_active IP Right Cessation
- 2000-09-08 CN CNB008126453A patent/CN1203855C/zh not_active Expired - Lifetime
- 2000-09-08 DE DE60025627T patent/DE60025627T2/de not_active Expired - Lifetime
- 2000-09-08 SK SK327-2002A patent/SK287154B6/sk not_active IP Right Cessation
- 2000-09-08 WO PCT/FI2000/000761 patent/WO2001019334A2/en active Search and Examination
- 2000-09-08 IL IL14837900A patent/IL148379A0/xx active IP Right Grant
- 2000-09-08 US US10/070,689 patent/US6730673B1/en not_active Expired - Lifetime
- 2000-09-08 HU HU0202749A patent/HU228340B1/hu unknown
- 2000-09-08 DK DK00958562T patent/DK1210085T3/da active
- 2000-09-08 BR BRPI0013924A patent/BRPI0013924B8/pt not_active IP Right Cessation
- 2000-09-08 CZ CZ20020788A patent/CZ303095B6/cs not_active IP Right Cessation
- 2000-09-08 TR TR2002/00620T patent/TR200200620T2/xx unknown
- 2000-09-08 RS YUP-169/02A patent/RS50445B/sr unknown
- 2000-09-08 KR KR20027002923A patent/KR100869752B1/ko active IP Right Grant
- 2000-09-08 AU AU70044/00A patent/AU771027B2/en not_active Expired
- 2000-09-08 ME MEP-2008-866A patent/ME00523B/me unknown
- 2000-09-08 JP JP2001522969A patent/JP4708648B2/ja not_active Expired - Lifetime
- 2000-09-08 CA CA002382013A patent/CA2382013C/en not_active Expired - Lifetime
- 2000-09-08 ES ES00958562T patent/ES2256034T3/es not_active Expired - Lifetime
- 2000-09-08 SI SI200030801T patent/SI1210085T1/sl unknown
- 2000-09-08 AT AT00958562T patent/ATE315937T1/de active
- 2000-09-08 EE EEP200200129A patent/EE05375B1/xx unknown
- 2000-09-08 MX MXPA02002423A patent/MXPA02002423A/es active IP Right Grant
- 2000-09-08 EA EA200200348A patent/EA005067B1/ru not_active IP Right Cessation
- 2000-09-08 PT PT00958562T patent/PT1210085E/pt unknown
- 2000-09-08 EP EP00958562A patent/EP1210085B1/en not_active Expired - Lifetime
- 2000-09-08 PL PL354028A patent/PL202356B1/pl unknown
-
2002
- 2002-02-26 IL IL148379A patent/IL148379A/en unknown
- 2002-03-05 NO NO20021090A patent/NO331989B1/no not_active IP Right Cessation
- 2002-03-05 ZA ZA200201828A patent/ZA200201828B/xx unknown
- 2002-03-06 IS IS6296A patent/IS2244B/is unknown
- 2002-04-05 BG BG106589A patent/BG65827B1/bg unknown
- 2002-04-08 HR HR20020298A patent/HRP20020298B1/xx not_active IP Right Cessation
-
2003
- 2003-02-18 HK HK03101189.6A patent/HK1049282B/zh not_active IP Right Cessation
- 2003-11-10 US US10/703,565 patent/US6943164B2/en not_active Expired - Lifetime
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998001111A1 (en) * | 1996-07-05 | 1998-01-15 | Orion-Yhtymä Oy | Transdermal compositions containing levosimendan |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100869752B1 (ko) | 레보시멘단의 약학적 액제 | |
US6548079B1 (en) | Moxifloxacin formulation containing common salt | |
EA033988B1 (ru) | Инъецируемые фармацевтические композиции лефамулина | |
BG107748A (bg) | Фармацевтичен състав на дронедарон за парентерално приложение | |
AU740291B2 (en) | Stabilized pharmaceutical compositions based on quinupristine and on dalfopristine and their preparation | |
US20060252804A1 (en) | Flupirtin injectable galenic form | |
US20230068866A1 (en) | Daptomycin formulation | |
US6187746B1 (en) | Pharmaceutical compositions based on dalfopristine and on quinupristine, and preparation thereof | |
CA2142445C (en) | Injection solutions of azosemide which are ready for injection | |
CN1611219A (zh) | 左西孟旦药物组合物及其制备方法 | |
EA023081B1 (ru) | Инъекционная лекарственная форма флупиртина |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E902 | Notification of reason for refusal | ||
E601 | Decision to refuse application | ||
J201 | Request for trial against refusal decision | ||
AMND | Amendment | ||
B701 | Decision to grant | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20121102 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20131031 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20141107 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20151105 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20161104 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20171102 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20181101 Year of fee payment: 11 |